Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.826768
Keywords
acute myeloid leukaemia; immunotherapy; biomarkers; checkpoint inhibition; T cell directed therapy
Categories
Ask authors/readers for more resources
This article provides an overview of recent advancements in immunotherapy for AML, focusing on biomarkers of response. The topics covered include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, cellular therapy, and the development of predictive biomarkers for response in each class.
Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available